Flexion Therapeutics, Inc.
Dec 9, 2016

Flexion Therapeutics to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference

BURLINGTON, Mass., Dec. 09, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will provide a company overview at the BMO Capital Markets Prescriptions for Success Healthcare Conference on Wednesday, December 14, 2016 at 8:30 a.m. Eastern Time at the InterContinental New York Barclay Hotel in New York.

To access the live webcast and subsequent archived recordings for the presentation, please visit the Flexion website at http://flexiontherapeutics.com/.

About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA). The company's lead product candidate, ZilrettaTM (FX006) is being investigated for its potential to provide improved analgesic therapy for the millions of U.S. patients who receive intra-articular injections for knee OA pain annually.

Media Contact:

Danielle Lewis
Lazar Partners
T: 212-867-1768 
flexionpr@lazarpartners.com

Investor Contact:

David Carey
Lazar Partners 
T: 212-867-1768 
dcarey@lazarpartners.com

Corporate Contacts:

Fred Driscoll
Chief Financial Officer
Flexion Therapeutics, Inc.
T: 781-305-7763
fdriscoll@flexiontherapeutics.com

Scott Young
Sr. Director, Corporate Communications & Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
syoung@flexiontherapeutics.com